SCHEMBL1065376

SCHEMBL1065376

CCOC(=O)/C=C(/C)Oc1ccccc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.41
FAAH O00519 9/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
RAB9A P51151 4/20 0.41
ALDH1A1 P00352 2/20 0.41
NPC1 O15118 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
MAPT P10636 3/20 0.40
KDM4E B2RXH2 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
POLB P06746 1/20 0.40
PKM P14618 1/20 0.40
GALK1 P51570 1/20 0.40
CCR6 P51684 1/20 0.40
BLM P54132 1/20 0.40
MCL1 Q07820 1/20 0.40
HKDC1 Q2TB90 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1065377 1.00 KMT2A (0.41) KMT2AFAAHSMN1; SMN2RAB9AALDH1A1
SCHEMBL1069104 0.89 SMN1; SMN2 (0.40) KMT2ASMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL1069102 0.89 SMN1; SMN2 (0.40) KMT2ASMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL1069105 0.89 SMN1; SMN2 (0.40) KMT2ASMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL1065610 0.86 TDP1 (0.46) KMT2ASMN1; SMN2RAB9AALDH1A1MAPT
SCHEMBL1065614 0.86 TDP1 (0.46) KMT2ASMN1; SMN2RAB9AALDH1A1MAPT
SCHEMBL1065611 0.86 TDP1 (0.46) KMT2ASMN1; SMN2RAB9AALDH1A1MAPT
SCHEMBL1068515 0.86 CYP4F2 (0.41) KMT2ARAB9AALDH1A1CYP1A2CYP2C19
SCHEMBL1068513 0.86 CYP4F2 (0.41) KMT2ARAB9AALDH1A1CYP1A2CYP2C19
SCHEMBL1067420 0.86 MAPT (0.43) KMT2AFAAHRAB9AALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2274297-B1 PYRROLIDINONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2012-05-09 EP disclosed
EP-2274297-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-19 EP disclosed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 KMT2A 2072/4885FAAH 4624/4885SMN1; SMN2 2392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.